Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

This review discusses recent advances in monophosphate prodrug strategies for HCV drug discovery, aiming to enhance oral absorption and stability, and reports no new clinical results.

This study found that methadone use in HCV-infected male veterans was associated with a significant increase in the risk of advanced liver fibrosis.

Androgen lowering medications don't significantly change HCV-related liver cancer risk in men.

In this study, 97% of patients undergoing pegylated interferon alfa2a and ribavirin therapy for chronic hepatitis C experienced one or more skin-related side effects, with hair loss being the most common.

This case report details the first known instance of interferon-induced lichen planus in a seronegative HCV patient with metastatic renal cell carcinoma.

Lichen Planus is a less common condition affecting skin and mucous membranes, with various types and associated risk factors, challenging to diagnose, significantly impacts life quality, and may have a risk of cancerous changes in oral lesions.

This case report documents a reversible instance of complete body hair loss (alopecia universalis) in a patient undergoing chronic hepatitis C treatment with pegylated interferon alpha-2b and ribavirin, with hair regrowth observed within three months after therapy completion.

In this study, researchers found that hepatitis C virus infection is a significant risk factor for sporadic porphyria cutanea tarda, suggesting familial cases might be more prevalent in areas with low hepatitis C infection rates.

In this study, a high daily dose of interferon alfa-2b administered initially six times a week for two weeks followed by thrice weekly for 12 weeks was most effective in sustaining normal ALT values in patients.

This study reported that while lichen planus was not significantly linked to hepatitis C virus infection, pruritus, dry skin, and hair loss were more common in HCV patients post-interferon treatment.

This article reviews the association between hepatitis C virus and systemic disorders like mixed cryoglobulinemia, highlighting potential autoimmune side effects from interferon-a2b treatments, and reports no new clinical results.

This review discusses zinc supplementation as a complementary therapy for chronic hepatitis C, noting its potential benefits in improving treatment outcomes and reducing side effects, but reports no new clinical results.

This case report highlights lichen planus pigmentosus in a 60-year-old man, which was linked to previously undetected hepatitis C infection and liver cirrhosis, suggesting a need for hepatitis C testing in patients with similar dermatological manifestations.

In this study of Egyptian patients on hepatitis C treatment, 34% experienced skin-related side effects from sofosbuvir and daclatasvir, such as itching and hyperpigmentation, but most reactions were mild and reversible without needing to stop therapy.

This study found that injecting drug users attending an oral substitution therapy center often experience skin lesions, which negatively impact their psychosocial health and quality of life.

This case report highlights that a patient developed alopecia areata following treatment with sofosbuvir and ribavirin for chronic hepatitis C.

This case study reports an unusual presentation of erosive lichen planus of the scalp linked to hepatitis C in a patient, highlighting challenges in establishing a definitive correlation between the two conditions.

In this study, researchers using network pharmacology and molecular docking methods found that compounds from Avicennia Marina could inhibit hepatitis C virus infection by targeting key proteins such as AKT1 and TNF-α, showing potential for anti-HCV treatments.

This study suggests that finasteride use is not significantly associated with a reduced risk of advanced hepatic fibrosis or inflammation in HCV-positive males, with ethnically-divergent findings for methadone requiring further investigation.

This study found that the CYP3A4 rs4646437 genotype was significantly associated with ALT elevation in Japanese patients undergoing asunaprevir plus daclatasvir therapy for chronic HCV infection, suggesting genotyping may help in monitoring patients safely.

This study found that dermatological adverse events from interferon-alpha/ribavirin treatment for chronic hepatitis C are associated with factors like older age, pre-existing skin conditions, cirrhosis, and the use of pegylated interferon formulations.

In this report, a case of a bullous lesion developed at the injection site in a patient treated with PEG-IFN-α-2a for chronic hepatitis C was described.

This review examines the spontaneous clearance of hepatitis C virus and factors such as IL-28B genetic polymorphism, which have been associated with this outcome, and reports no new clinical results.

This study found that betulinic acid inhibits hepatitis C virus replication by suppressing the NF-κB- and ERK1/2-mediated COX-2 pathway, suggesting its potential as a therapeutic supplement.

This study suggests that supplemental testosterone therapy in men with hepatitis C virus may be associated with a modest reduction in hepatocellular carcinoma risk, challenging concerns about its potential to increase cancer risk.

This abstract discusses the dermatological symptoms associated with hepatitis C virus infections but reports no new research findings.

In this study, peginterferon alfa-2b plus ribavirin therapy in hepatitis C patients was associated with serious adverse drug reactions in 20% of cases, highlighting differences from clinical trial findings.

This case study suggests that treatment with Pil-Food, intended for hair loss prevention, may have triggered postinfantile giant cell hepatitis with autoimmune characteristics, which showed a rapid and effective response to corticosteroid therapy.

This study found that supplementing soybean oil significantly increased the production of the cyclosporine A derivative [(4'-OH)MeLeu]4-CsA by 55.6%, offering potential enhancements for its clinical application.

This review discusses the molecular mechanisms by which oncogenic viruses contribute to cancer development through manipulation of host cellular functions and highlights the need for further research into virus-associated cancers, reporting no new results.